TD Waterhouse Canada Inc. Invests $2.03 Million in Carlsmed, Inc. $CARL

TD Waterhouse Canada Inc. purchased a new stake in Carlsmed, Inc. (NASDAQ:CARL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 152,242 shares of the company’s stock, valued at approximately $2,026,000.

Separately, Kornitzer Capital Management Inc. KS bought a new stake in Carlsmed in the third quarter worth approximately $736,000.

Wall Street Analyst Weigh In

CARL has been the subject of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $24.00 price target on shares of Carlsmed in a research note on Monday, December 15th. Wall Street Zen downgraded Carlsmed from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. The Goldman Sachs Group restated a “buy” rating and issued a $20.00 target price on shares of Carlsmed in a research note on Friday, January 9th. Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a report on Monday, December 22nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $20.00 price objective (up from $18.00) on shares of Carlsmed in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Carlsmed has an average rating of “Moderate Buy” and an average target price of $21.33.

Carlsmed Price Performance

Shares of NASDAQ:CARL opened at $12.42 on Friday. The company has a quick ratio of 11.91, a current ratio of 12.03 and a debt-to-equity ratio of 0.14. The company has a fifty day moving average of $13.41. Carlsmed, Inc. has a fifty-two week low of $11.45 and a fifty-two week high of $17.19. The company has a market capitalization of $330.25 million and a PE ratio of -3.72.

Carlsmed (NASDAQ:CARL) last issued its earnings results on Thursday, November 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).